{"id":53785,"date":"2023-02-09T13:02:38","date_gmt":"2023-02-09T12:02:38","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/prokarium-announces-30-million-financing-to-deliver-lead-program-into-clinic-and-build-novel-therapeutic-platform\/"},"modified":"2023-02-09T13:02:38","modified_gmt":"2023-02-09T12:02:38","slug":"prokarium-announces-30-million-financing-to-deliver-lead-program-into-clinic-and-build-novel-therapeutic-platform","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/prokarium-announces-30-million-financing-to-deliver-lead-program-into-clinic-and-build-novel-therapeutic-platform\/","title":{"rendered":"Prokarium Announces $30 Million Financing to Deliver Lead Program into Clinic and Build Novel Therapeutic Platform"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\nProkarium\u2019s mission is to re-engineer evolution into a synthetic biology platform for novel immunotherapies\n<\/li>\n<li>\nProceeds will support clinical development of the Company\u2019s lead oncology candidate in non-muscle invasive bladder cancer and accelerate platform discovery\n<\/li>\n<li>\nProfessor Adrian Hayday, PhD and Sam Chang, MD join as scientific advisors\n<\/li>\n<\/ul>\n<p>LONDON&#8211;(BUSINESS WIRE)&#8211;Prokarium, a biopharmaceutical company leading the oncology field of microbial immunotherapy, has raised $30 million in new funding. This follows Prokarium\u2019s announcement of <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fprokarium-and-ginkgo-bioworks-announce-partnership-to-discover-multiple-targets-for-rna-therapeutics-and-immuno-oncology-301715856.html&amp;esheet=53302565&amp;newsitemid=20230209005006&amp;lan=en-US&amp;anchor=partnering+with+Ginkgo+Bioworks&amp;index=1&amp;md5=f7d726f1095abd9ba52bd0fa3444cbcd\" rel=\"nofollow noopener\" shape=\"rect\">partnering with Ginkgo Bioworks<\/a> to leverage its world-class Foundry and extensive Codebase to develop a bactofection platform technology.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230209005006\/en\/1705685\/5\/Prokarium_-_Main_Logo_-_for_white_background.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230209005006\/en\/1705685\/21\/Prokarium_-_Main_Logo_-_for_white_background.jpg\"><\/a><\/p>\n<p>\n\u201cWe are excited to advance our vision to create living cures,\u201d said Kristen Albright, PharmD, Chief Executive Officer of Prokarium. \u201cProceeds of this financing will fund our lead oncology program entering clinical development this year and enable platform expansion for the delivery of novel therapeutic payloads, including RNA, via our proprietary bacteria. With Ginkgo\u2019s partnership and their expertise in strain engineering and optimization we look forward to working towards unlocking a new generation of immuno-oncology therapeutics.\u201d\n<\/p>\n<p>\nProkarium\u2019s lead program has the potential to transform the treatment paradigm in bladder cancer, one of the costliest cancers to treat, in its efforts to become the new standard-of-care in a market that has seen little innovation in over 30 years and to offer advanced therapies an alternative to Bacillus Calmette-Gu\u00e9rin (BCG). Prokarium\u2019s pipeline leverages evolutionary advantages of a proprietary strain of <i>Salmonella<\/i> and combines them with bespoke synthetic circuits to deliver diverse therapeutic cargo for difficult-to-treat cancers.\n<\/p>\n<p>\n\u201cWe believe Prokarium is a truly differentiated company,\u201d added Thomas Eldered, Executive Chairman, Flerie Invest. \u201cThe new funds and Prokarium\u2019s partnership with Ginkgo Bioworks will accelerate the cutting-edge innovation essential to lead the advancements in the field of synthetic biology and immunotherapy for years to come.\u201d\n<\/p>\n<p>\n\u201cOur partnership with Prokarium will utilize Ginkgo\u2019s leading platform capabilities and services to pioneer technological developments that we believe will revolutionize the immuno-oncology field,\u201d added Ena Cratsenburg, Chief Business Officer at Ginkgo Bioworks. \u201cGinkgo is excited to partner with Prokarium to work to build a versatile <i>Salmonella<\/i>-based bactofection platform capable of delivering targeted, localized RNA therapeutics.\u201d\n<\/p>\n<p>\nIn addition to the financing, Prokarium has announced the addition of two scientific advisors, Professor Adrian Hayday, PhD and Sam Chang, MD, MBA. \u201cWe are thrilled to welcome Adrian and Sam as advisors as we transition into a clinical-stage company,\u201d concluded Albright. \u201cAdrian brings the deep immunology and immunotherapy expertise, and Sam possesses invaluable clinical experience being involved in numerous bladder cancer clinical trials.\u201d Professor Hayday is the founding Chair of Peter Gorer Department of Immunobiology at King\u2019s College London and is currently Principal Group Leader at the Francis Crick Institute. Sam currently serves as the Chief Surgical Officer at the Vanderbilt Ingram Cancer Center.\n<\/p>\n<p>\n<b>About Prokarium<br \/>\n<br \/><\/b>Prokarium is a biopharmaceutical company leading the oncology field of microbial immunotherapy with the vision to create living cures. The Company\u2019s pipeline is designed to unlock a new generation of immuno-oncology therapeutics by re-engineering evolution into a synthetic biology platform. Prokarium\u2019s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects. Prokarium is based in London, UK. For further information, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.prokarium.com&amp;esheet=53302565&amp;newsitemid=20230209005006&amp;lan=en-US&amp;anchor=www.prokarium.com&amp;index=2&amp;md5=ffb3f966ff09bb8cd1fee1afb1922821\" rel=\"nofollow noopener\" shape=\"rect\">www.prokarium.com<\/a>.\n<\/p>\n<p>\n<b>About Flerie Invest<br \/>\n<br \/><\/b>Flerie Invest is an active long-term global biotech and pharma investor based in Stockholm and London managing a portfolio of over 30 companies in Europe, Israel and the US. The focus is on enabling pioneering organisations operating in the drug development and services space to succeed by providing them with resources and expertise. The portfolio includes a wide range of areas including immuno- oncology, metabolic diseases and biologics development and manufacturing organisations which have the potential to make a significant impact in health and wellbeing. Flerie Invest was founded in 2011 by Thomas Eldered, who also co-founded and built Recipharm to be one of the world\u2019s top five pharmaceutical contract manufacturers. For more information, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.flerie.com&amp;esheet=53302565&amp;newsitemid=20230209005006&amp;lan=en-US&amp;anchor=www.flerie.com&amp;index=3&amp;md5=9740da6468d475efde5300287e59f1d6\" rel=\"nofollow noopener\" shape=\"rect\">www.flerie.com<\/a>.\n<\/p>\n<p>\n<b>About Ginkgo Bioworks<br \/>\n<br \/><\/b>Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo\u2019s biosecurity and public health unit, Concentric by Ginkgo, is building global infrastructure for biosecurity to empower governments, communities, and public health leaders to prevent, detect and respond to a wide variety of biological threats. For more information, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ginkgobioworks.com%2F&amp;esheet=53302565&amp;newsitemid=20230209005006&amp;lan=en-US&amp;anchor=ginkgobioworks.com&amp;index=4&amp;md5=09518b152e93ca1829f998fc6f8a1c5f\" rel=\"nofollow noopener\" shape=\"rect\">ginkgobioworks.com<\/a> and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.concentricbyginkgo.com%2F&amp;esheet=53302565&amp;newsitemid=20230209005006&amp;lan=en-US&amp;anchor=concentricbyginkgo.com&amp;index=5&amp;md5=72d3df5bfa73307bcc9dca45a8e24596\" rel=\"nofollow noopener\" shape=\"rect\">concentricbyginkgo.com<\/a>, read our blog, or follow us on social media channels such as Twitter <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fginkgo&amp;esheet=53302565&amp;newsitemid=20230209005006&amp;lan=en-US&amp;anchor=%28%40Ginkgo&amp;index=6&amp;md5=7aa355dabf1c951f09453a08f720968a\" rel=\"nofollow noopener\" shape=\"rect\">(@Ginkgo<\/a> and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fconcentricbygbw&amp;esheet=53302565&amp;newsitemid=20230209005006&amp;lan=en-US&amp;anchor=%40ConcentricByGBW&amp;index=7&amp;md5=d739a292ea86f737ededc6f0430ee5d9\" rel=\"nofollow noopener\" shape=\"rect\">@ConcentricByGBW<\/a>), Instagram (<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fginkgobioworks%2F&amp;esheet=53302565&amp;newsitemid=20230209005006&amp;lan=en-US&amp;anchor=%40GinkgoBioworks&amp;index=8&amp;md5=2ea9706fc0edd2dc32ad2f30d851e211\" rel=\"nofollow noopener\" shape=\"rect\">@GinkgoBioworks<\/a> and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fconcentricbyginkgo%2F&amp;esheet=53302565&amp;newsitemid=20230209005006&amp;lan=en-US&amp;anchor=%40ConcentricByGinkgo&amp;index=9&amp;md5=83eaa720e4dc59589f386c3e025cdba4\" rel=\"nofollow noopener\" shape=\"rect\">@ConcentricByGinkgo<\/a>), or <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fginkgo-bioworks%2Fmycompany%2F&amp;esheet=53302565&amp;newsitemid=20230209005006&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=10&amp;md5=0e6b0d5da804c9b83e6cafa5e1339689\" rel=\"nofollow noopener\" shape=\"rect\">LinkedIn<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>PROKARIUM CONTACT:<\/b><br \/>Lisa Stone<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#105;&#108;&#116;o&#x3a;&#x6c;&#x69;&#115;&#97;&#46;s&#x74;&#x6f;&#x6e;&#101;&#64;p&#x72;&#x6f;&#x6b;&#97;&#114;&#105;u&#x6d;&#x2e;&#x63;&#111;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x6c;&#105;&#x73;&#97;&#46;&#x73;&#116;o&#x6e;&#101;&#x40;&#x70;r&#x6f;&#107;a&#x72;&#105;&#x75;&#x6d;&#46;&#x63;&#111;m<\/a>\n<\/p>\n<p>\n<b>GINKGO BIOWORKS CONTACT:<\/b><br \/><a target=\"_blank\" href=\"&#x6d;&#97;i&#x6c;&#116;o&#x3a;&#x70;&#114;&#x65;&#x73;&#115;&#64;&#x67;&#105;n&#x6b;&#x67;&#111;&#x62;&#x69;&#111;w&#x6f;&#114;k&#x73;&#x2e;&#99;&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x70;r&#x65;&#115;&#x73;&#x40;g&#x69;&#110;&#x6b;&#x67;o&#x62;&#105;&#x6f;&#x77;o&#x72;&#107;&#x73;&#x2e;c&#x6f;&#109;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Prokarium\u2019s mission is to re-engineer evolution into a synthetic biology platform for novel immunotherapies Proceeds will support clinical development of the Company\u2019s lead oncology candidate in non-muscle invasive bladder cancer and accelerate platform discovery Professor Adrian Hayday, PhD and Sam Chang, MD join as scientific advisors LONDON&#8211;(BUSINESS WIRE)&#8211;Prokarium, a biopharmaceutical company leading the oncology field &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/prokarium-announces-30-million-financing-to-deliver-lead-program-into-clinic-and-build-novel-therapeutic-platform\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53785","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Prokarium Announces $30 Million Financing to Deliver Lead Program into Clinic and Build Novel Therapeutic Platform - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/prokarium-announces-30-million-financing-to-deliver-lead-program-into-clinic-and-build-novel-therapeutic-platform\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prokarium Announces $30 Million Financing to Deliver Lead Program into Clinic and Build Novel Therapeutic Platform - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Prokarium\u2019s mission is to re-engineer evolution into a synthetic biology platform for novel immunotherapies Proceeds will support clinical development of the Company\u2019s lead oncology candidate in non-muscle invasive bladder cancer and accelerate platform discovery Professor Adrian Hayday, PhD and Sam Chang, MD join as scientific advisors LONDON&#8211;(BUSINESS WIRE)&#8211;Prokarium, a biopharmaceutical company leading the oncology field ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/prokarium-announces-30-million-financing-to-deliver-lead-program-into-clinic-and-build-novel-therapeutic-platform\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-09T12:02:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230209005006\/en\/1705685\/21\/Prokarium_-_Main_Logo_-_for_white_background.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prokarium-announces-30-million-financing-to-deliver-lead-program-into-clinic-and-build-novel-therapeutic-platform\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prokarium-announces-30-million-financing-to-deliver-lead-program-into-clinic-and-build-novel-therapeutic-platform\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Prokarium Announces $30 Million Financing to Deliver Lead Program into Clinic and Build Novel Therapeutic Platform\",\"datePublished\":\"2023-02-09T12:02:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prokarium-announces-30-million-financing-to-deliver-lead-program-into-clinic-and-build-novel-therapeutic-platform\\\/\"},\"wordCount\":789,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prokarium-announces-30-million-financing-to-deliver-lead-program-into-clinic-and-build-novel-therapeutic-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230209005006\\\/en\\\/1705685\\\/21\\\/Prokarium_-_Main_Logo_-_for_white_background.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prokarium-announces-30-million-financing-to-deliver-lead-program-into-clinic-and-build-novel-therapeutic-platform\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prokarium-announces-30-million-financing-to-deliver-lead-program-into-clinic-and-build-novel-therapeutic-platform\\\/\",\"name\":\"Prokarium Announces $30 Million Financing to Deliver Lead Program into Clinic and Build Novel Therapeutic Platform - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prokarium-announces-30-million-financing-to-deliver-lead-program-into-clinic-and-build-novel-therapeutic-platform\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prokarium-announces-30-million-financing-to-deliver-lead-program-into-clinic-and-build-novel-therapeutic-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230209005006\\\/en\\\/1705685\\\/21\\\/Prokarium_-_Main_Logo_-_for_white_background.jpg\",\"datePublished\":\"2023-02-09T12:02:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prokarium-announces-30-million-financing-to-deliver-lead-program-into-clinic-and-build-novel-therapeutic-platform\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prokarium-announces-30-million-financing-to-deliver-lead-program-into-clinic-and-build-novel-therapeutic-platform\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prokarium-announces-30-million-financing-to-deliver-lead-program-into-clinic-and-build-novel-therapeutic-platform\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230209005006\\\/en\\\/1705685\\\/21\\\/Prokarium_-_Main_Logo_-_for_white_background.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230209005006\\\/en\\\/1705685\\\/21\\\/Prokarium_-_Main_Logo_-_for_white_background.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prokarium-announces-30-million-financing-to-deliver-lead-program-into-clinic-and-build-novel-therapeutic-platform\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prokarium Announces $30 Million Financing to Deliver Lead Program into Clinic and Build Novel Therapeutic Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Prokarium Announces $30 Million Financing to Deliver Lead Program into Clinic and Build Novel Therapeutic Platform - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/prokarium-announces-30-million-financing-to-deliver-lead-program-into-clinic-and-build-novel-therapeutic-platform\/","og_locale":"en_US","og_type":"article","og_title":"Prokarium Announces $30 Million Financing to Deliver Lead Program into Clinic and Build Novel Therapeutic Platform - Pharma Trend","og_description":"Prokarium\u2019s mission is to re-engineer evolution into a synthetic biology platform for novel immunotherapies Proceeds will support clinical development of the Company\u2019s lead oncology candidate in non-muscle invasive bladder cancer and accelerate platform discovery Professor Adrian Hayday, PhD and Sam Chang, MD join as scientific advisors LONDON&#8211;(BUSINESS WIRE)&#8211;Prokarium, a biopharmaceutical company leading the oncology field ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/prokarium-announces-30-million-financing-to-deliver-lead-program-into-clinic-and-build-novel-therapeutic-platform\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-09T12:02:38+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230209005006\/en\/1705685\/21\/Prokarium_-_Main_Logo_-_for_white_background.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/prokarium-announces-30-million-financing-to-deliver-lead-program-into-clinic-and-build-novel-therapeutic-platform\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/prokarium-announces-30-million-financing-to-deliver-lead-program-into-clinic-and-build-novel-therapeutic-platform\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Prokarium Announces $30 Million Financing to Deliver Lead Program into Clinic and Build Novel Therapeutic Platform","datePublished":"2023-02-09T12:02:38+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/prokarium-announces-30-million-financing-to-deliver-lead-program-into-clinic-and-build-novel-therapeutic-platform\/"},"wordCount":789,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/prokarium-announces-30-million-financing-to-deliver-lead-program-into-clinic-and-build-novel-therapeutic-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230209005006\/en\/1705685\/21\/Prokarium_-_Main_Logo_-_for_white_background.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/prokarium-announces-30-million-financing-to-deliver-lead-program-into-clinic-and-build-novel-therapeutic-platform\/","url":"https:\/\/pharma-trend.com\/en\/prokarium-announces-30-million-financing-to-deliver-lead-program-into-clinic-and-build-novel-therapeutic-platform\/","name":"Prokarium Announces $30 Million Financing to Deliver Lead Program into Clinic and Build Novel Therapeutic Platform - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/prokarium-announces-30-million-financing-to-deliver-lead-program-into-clinic-and-build-novel-therapeutic-platform\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/prokarium-announces-30-million-financing-to-deliver-lead-program-into-clinic-and-build-novel-therapeutic-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230209005006\/en\/1705685\/21\/Prokarium_-_Main_Logo_-_for_white_background.jpg","datePublished":"2023-02-09T12:02:38+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/prokarium-announces-30-million-financing-to-deliver-lead-program-into-clinic-and-build-novel-therapeutic-platform\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/prokarium-announces-30-million-financing-to-deliver-lead-program-into-clinic-and-build-novel-therapeutic-platform\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/prokarium-announces-30-million-financing-to-deliver-lead-program-into-clinic-and-build-novel-therapeutic-platform\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230209005006\/en\/1705685\/21\/Prokarium_-_Main_Logo_-_for_white_background.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230209005006\/en\/1705685\/21\/Prokarium_-_Main_Logo_-_for_white_background.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/prokarium-announces-30-million-financing-to-deliver-lead-program-into-clinic-and-build-novel-therapeutic-platform\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Prokarium Announces $30 Million Financing to Deliver Lead Program into Clinic and Build Novel Therapeutic Platform"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53785","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53785"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53785\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53785"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53785"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53785"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}